GSK Hid Morning Sickness Drug's Birth Defect Risks: Suit

By Roxanne Palmer (October 25, 2011, 10:15 PM EDT) -- GlaxoSmithKline PLC and other pharmaceutical companies were hit with a suit Tuesday in Pennsylvania court alleging the companies and their predecessors negligently buried evidence showing the morning sickness drug thalidomide caused birth defects.

Thalidomide — which was developed by German company Gruenenthal GmbH, also named as a defendant — was never approved by the U.S. Food and Drug Administration, but the suit says as many as 2.5 million doses of the drug were distributed to more than 20,000 people, including pregnant women.

The complaint also names as defendants the U.S. wing of French drug giant Sanofi-Aventis SA and Avantor Performance Materials...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login